ArticleTranslational oncology2026
An immune related cell death index for prognostic stratification and immunotherapy response prediction in oral cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-related cell death (IRCD) plays a crucial role in the immune microenvironment, development, and deterioration of oral cancer. However, reliable immune-related cell death profiles have not been explored. In this study, based on multiple oral cancer datasets such as TCGA, tumors were divided into two immune subtypes, "Hot" and "Cold", using the ConsensusClusterPlus algorithm, and significant differences were found between the two in immune cell infiltration, microenvironment activity, and immunotherapy responsiveness. The immune-related cell death index (IRCDI) based on immune-related cell death gene (IRCDG) was further constructed to reveal that IRCDI can be used as an independent prognostic indicator and is closely related to immune activity, gene mutation characteristics and a variety of signaling pathways. Both single cell analysis and immunosubtype analysis showed that low IRCDI was closely related to enhanced immunocompetence. Although IRCDI has a limited predictive role in the TIDE algorithm, it has a good predictive ability in multiple real immunotherapy cohorts and shows specific sensitivity to different drugs, suggesting that IRCDI is expected to be an important biomarker to guide individualized treatment of oral cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.